Granted Patent B2

US 11,285,132 · App. 16/847,516 · Granted Mar 29, 2022

Inventors: Brian Lannutti (Solana Beach, CA); Katayoun Jessen (San Diego, CA); James Bradley Breitmeyer (San Diego, CA)

Assignee: Oncternal Therapeutics, Inc.

A61K31/404A61K31/4155A61K31/4439A61K31/496A61K31/5377A61K31/551A61K39/39558A61K45/06C07K16/2887C07K2317/24C07K2317/73

Abstract

Claims (14)

1. A method for inducing apoptosis in a cell comprising a myeloblast produced in acute myeloid leukemia or a lymphocyte produced in diffuse large B cell lymphoma, comprising contacting the cell with an effective amount of a combination of:

at least one therapeutic agent selected from the group consisting of bortezomib, idelalisib, vincristine, bendamustine, lidelalisib, PQR309, or selinexor; and

a compound having a structure:

or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof.

2. The method of claim 1 , wherein the compound has a structure:

3. The method of claim 1 , wherein the compound has a structure:

4. The method of claim 1 , wherein the cell is a myeloblast produced in acute myeloid leukemia.

5. The method of claim 1 , wherein the cell is a lymphocyte produced in diffuse large B cell lymphoma.

6. A pharmaceutical composition, comprising:

at least one therapeutic agent selected from the group consisting of bortezomib, idelalisib, vincristine, bendamustine, lidelalisib, PQR 309 , or selinexor; and

a compound having a structure:

or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof.

7. The pharmaceutical composition of claim 6 , wherein the compound has a structure:

8. The pharmaceutical composition of claim 6 , wherein the compound has a structure:

Assignments (3)

Continuity (9)